LIF is
making research and development of Sildenafil syrup and tablets.
Syldenafil
syrup is an orphan medicine used to treat Pulmonary Arterial Hypertension (PAH)*
of the newborn. This is developed with the Rosario ’s
National University ,
School of Sciences Biochemical
On the
other hand LIF is working on the development of Sildenafil tablets used to
treat erectile dysfunction.
* PAH is a
rare disease with an incidence of about 2-3 per million per year and a
prevalence of about 15 per million. Adult females are almost three times as
likely to present with PAH as adult males. The presentation of IPAH within
children is more evenly split along gender lines. (N. Rudarakanchana, R C Trembath, N. W. Morrel. New insights into the
pathogenesis and treatment of primary pulmonary hypertension)
No comments:
Post a Comment